{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:05:55Z","timestamp":1794254755698,"version":"4.9.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radiotherapy, chemotherapy, autologous\/allogeneic stem cell transplantation, and targeted drug therapy are currently available therapeutic options for multiple myeloma (MM), but the clinical outcome remains unsatisfactory owing to frequent occurrence of drug resistance. Anti apoptosis is one of the main mechanisms to mediate drug resistance. Studies have shown that MCL-1 plays a key role in the growth of cancer cells \u201cescaping\u201d drug attacks, but the underlying mechanism remains unclear. Our previous study demonstrated that lncRNA H19 was highly expressed in the serum of MM patients. Bioinformatics predicts that miR-29b-3p is the downstream target gene, and MCL-1 is the downstream target protein of miR-29b-3p. Therefore, we speculated that MCL-1 may be involved in the occurrence of drug resistance through epigenetics. On the basis of these previous findings, the present study was intended to explore the biological function of H19, interactions between the downstream target genes, and the effect of H19 on BTZ resistance of myeloma cells. In addition, in vivo experiments we have also confirmed that H19 promoted tumor growth and may develop resistance to bortezomib partly. It was found that H19 reduced cell sensitivity to the chemotherapeutic drug BTZ by working as a miRNA sponge to inhibit the expression of miR-29b-3p, enhance MCL-1 transcriptional translation and inhibit apoptosis. These findings may help gain insights into the molecular mechanism of acquired BTZ resistance and develop new drug targets for the clinical treatment of MM.<\/jats:p>","DOI":"10.1038\/s41419-018-1219-0","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T08:03:33Z","timestamp":1549440213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p"],"prefix":"10.1038","volume":"10","author":[{"given":"Yafang","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqing","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"1219_CR1","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00520-018-4137-x","volume":"26","author":"F Sparano","year":"2018","unstructured":"Sparano, F., Cavo, M., Niscola, P., Caravita, T. & Efficace, F. Patient-reported outcomes in relapsed\/refractory multiple myeloma: a systematic review. Support. Care Cancer 26, 2075\u20132090 (2018).","journal-title":"Support. Care Cancer"},{"key":"1219_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s11899-018-0443-0","volume":"13","author":"KB McCullough","year":"2018","unstructured":"McCullough, K. B., Hobbs, M. A., Abeykoon, J. P. & Kapoor, P. Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies. Curr. Hematol. Malig. Rep. 13, 114\u2013124 (2018).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"1219_CR3","doi-asserted-by":"crossref","unstructured":"Sun C. Y., et al. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis. Biosci. Rep. 37, pii: BSR20170304 (2017).","DOI":"10.1042\/BSR20170304"},{"key":"1219_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11936-018-0618-y","volume":"20","author":"DH Lee","year":"2018","unstructured":"Lee, D. H. & Fradley, M. G. Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention. Curr. Treat. Options Cardiovasc. Med. 20, 19 (2018).","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"1219_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.leukres.2011.09.011","volume":"36","author":"P Balsas","year":"2012","unstructured":"Balsas, P., Gal\u00e1n-Malo, P., Marzo, I. & Naval, J. Bortezomib resistance in a myeloma cell line is associated to PSM\u03b25 overexpression and polyploidy. Leuk. Res. 36, 212\u2013218 (2012).","journal-title":"Leuk. Res."},{"key":"1219_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","volume":"12","author":"CM Annunziata","year":"2007","unstructured":"Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115\u2013130 (2007).","journal-title":"Cancer Cell"},{"key":"1219_CR7","doi-asserted-by":"publisher","first-page":"29854","DOI":"10.1074\/jbc.M115.664953","volume":"290","author":"B Li","year":"2015","unstructured":"Li, B. et al. The nuclear Factor (Erythroid-derived 2)-like 2 and proteasome maturation protein axis mediate bortezomib resistance in multiple myeloma. J. Biol. Chem. 290, 29854\u201329868 (2015).","journal-title":"J. Biol. Chem."},{"key":"1219_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ccell.2015.09.010","volume":"28","author":"C Leung-Hagesteijn","year":"2015","unstructured":"Leung-Hagesteijn, C. et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 28, 541\u2013542 (2015).","journal-title":"Cancer Cell"},{"key":"1219_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2013.02.017","volume":"23","author":"L Lamy","year":"2013","unstructured":"Lamy, L. et al. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 23, 435\u2013449 (2013).","journal-title":"Cancer Cell"},{"key":"1219_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","volume":"123","author":"Z Tian","year":"2014","unstructured":"Tian, Z. et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123, 706\u2013716 (2014).","journal-title":"Blood"},{"key":"1219_CR11","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/leu.2010.137","volume":"24","author":"M Ri","year":"2010","unstructured":"Ri, M. et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24, 1506\u20131512 (2010).","journal-title":"Leukemia"},{"key":"1219_CR12","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1182\/blood-2012-05-426924","volume":"120","author":"DI Lichter","year":"2012","unstructured":"Lichter, D. I. et al. Sequence analysis of \u03b2-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood 120, 4513\u20134516 (2012).","journal-title":"Blood"},{"key":"1219_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.leukres.2005.06.014","volume":"30","author":"M Politou","year":"2006","unstructured":"Politou, M. et al. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib. Leuk. Res. 30, 240\u2013241 (2006).","journal-title":"Leuk. Res."},{"key":"1219_CR14","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/1541-7786.MCR-08-0108","volume":"6","author":"S Markovina","year":"2008","unstructured":"Markovina, S. et al. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol. Cancer Res. 6, 1356\u20131364 (2008).","journal-title":"Mol. Cancer Res."},{"key":"1219_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467\u2013472 (2011).","journal-title":"Nature"},{"key":"1219_CR16","first-page":"4585","volume":"15","author":"Z Wang","year":"2018","unstructured":"Wang, Z. & Ji, F. Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21. Oncol. Lett. 15, 4585\u20134591 (2018).","journal-title":"Oncol. Lett."},{"key":"1219_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2147\/OTT.S153814","volume":"11","author":"C Yang","year":"2018","unstructured":"Yang, C. et al. Kanglaite reverses multidrug resistance of HCC by inducing apoptosis and cell cycle arrest via PI3K\/AKT pathway. OncoTargets Ther. 11, 983\u2013996 (2018).","journal-title":"OncoTargets Ther."},{"key":"1219_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0528-9","volume":"18","author":"A Vazanova","year":"2018","unstructured":"Vazanova, A. et al. Differential mRNA expression of the main apoptotic proteins in normal and malignant cells and its relation to in vitro resistance. Cancer Cell Int. 18, 33 (2018).","journal-title":"Cancer Cell Int."},{"key":"1219_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pharmthera.2014.08.003","volume":"145","author":"J Belmar","year":"2015","unstructured":"Belmar, J. & Fesik, S. W. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol. Ther. 145, 76\u201384 (2015).","journal-title":"Pharmacol. Ther."},{"key":"1219_CR20","first-page":"1","volume":"11","author":"L Chen","year":"2017","unstructured":"Chen, L., Hu, N., Wang, C., Zhao, H. & Gu, Y. Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression. Cell Cycle 11, 1\u201328 (2017).","journal-title":"Cell Cycle"},{"key":"1219_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3727\/096504017X14886679715637","volume":"25","author":"YB Meng","year":"2017","unstructured":"Meng, Y. B. et al. Long noncoding RNA CRNDE promotes multiple myeloma cell growth by suppressing miR-451. Oncol. Res. 25, 1207\u20131214 (2017).","journal-title":"Oncol. Res."},{"key":"1219_CR22","doi-asserted-by":"crossref","unstructured":"Jafarlou M., et al. Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia. Artif. Cells Nanomed. Biotechnol. 46,1\u20137 (2018).","DOI":"10.1080\/21691401.2017.1392969"},{"key":"1219_CR23","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","volume":"129","author":"VA Gupta","year":"2017","unstructured":"Gupta, V. A. et al. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood 129, 1969\u20131979 (2017).","journal-title":"Blood"},{"key":"1219_CR24","doi-asserted-by":"crossref","unstructured":"Janakiraman H., et al. The long (lncRNA) and short (miRNA) of it: TGF\u03b2-mediated control of RNA-binding proteins and noncoding RNAs. Mol. Cancer Res. 16, 567\u2013579 (2018).","DOI":"10.1158\/1541-7786.MCR-17-0547"},{"key":"1219_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.358","volume":"8","author":"N Yang","year":"2017","unstructured":"Yang, N. et al. LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN\/PI3K\/AKT pathway in multiple myeloma. Cell Death Dis. 8, e2975 (2017).","journal-title":"Cell Death Dis."},{"key":"1219_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/bjh.14882","volume":"179","author":"H Handa","year":"2017","unstructured":"Handa, H. et al. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. Br. J. Haematol. 179, 449\u2013460 (2017).","journal-title":"Br. J. Haematol."},{"key":"1219_CR27","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/stem.1989","volume":"33","author":"W Zhuang","year":"2015","unstructured":"Zhuang, W. et al. Upregulation of lncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription. Stem Cells 33, 1985\u20131997 (2015).","journal-title":"Stem Cells"},{"key":"1219_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/CBM-160158","volume":"18","author":"X Shen","year":"2017","unstructured":"Shen, X. et al. Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. Cancer Biomark. 18, 257\u2013263 (2017).","journal-title":"Cancer Biomark."},{"key":"1219_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0444-8","volume":"14","author":"KY Wong","year":"2015","unstructured":"Wong, K. Y. et al. Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. Mol. Cancer 14, 175 (2015).","journal-title":"Mol. Cancer"},{"key":"1219_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ejh.12908","volume":"99","author":"L Sedlarikova","year":"2017","unstructured":"Sedlarikova, L. et al. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. Eur. J. Haematol. 99, 223\u2013233 (2017).","journal-title":"Eur. J. Haematol."},{"key":"1219_CR31","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3892\/or.2015.3899","volume":"33","author":"H Sun","year":"2015","unstructured":"Sun, H. et al. H19 lncRNA mediates 17\u03b2-estradiol-induced cell proliferation in MCF-7 breast cancer cells. Oncol. Rep. 33, 3045\u20133052 (2015).","journal-title":"Oncol. Rep."},{"key":"1219_CR32","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.7314\/APJCP.2014.15.6.2565","volume":"15","author":"J Lv","year":"2014","unstructured":"Lv, J., Yu, Y. Q., Li, S. Q., Luo, L. & Wang, Q. Aflatoxin B1 promotes cell growth and invasion in hepatocellular carcinoma HepG2 cells through H19 and E2F1. Asian Pac. J. Cancer Prev. 15, 2565\u20132570 (2014).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"1219_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13277-015-3779-2","volume":"37","author":"C Liu","year":"2016","unstructured":"Liu, C. et al. H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation. Tumour Biol. 37, 263\u2013270 (2016).","journal-title":"Tumour Biol."},{"key":"1219_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cca.2018.02.019","volume":"480","author":"Y Pan","year":"2018","unstructured":"Pan, Y. et al. Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. Clin. Chim. Acta 480, 199\u2013205 (2018).","journal-title":"Clin. Chim. Acta"},{"key":"1219_CR35","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.bbamcr.2017.08.001","volume":"1864","author":"M Lv","year":"2017","unstructured":"Lv, M. et al. lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA. Biochim. Biophys. Acta 1864, 1887\u20131899 (2017).","journal-title":"Biochim. Biophys. Acta"},{"key":"1219_CR36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ygyno.2014.06.024","volume":"134","author":"A Sugio","year":"2014","unstructured":"Sugio, A. et al. BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer. Gynecol. Oncol. 134, 615\u2013623 (2014).","journal-title":"Gynecol. Oncol."},{"key":"1219_CR37","first-page":"1","volume":"27","author":"YW Choi","year":"2018","unstructured":"Choi, Y. W. et al. Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma. Leuk. Lymphoma 27, 1\u20139 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"1219_CR38","first-page":"1","volume":"29","author":"L Chen","year":"2018","unstructured":"Chen, L., Hu, N., Wang, C., Zhao, H. & Gu, Y. Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression. Cell Cycle 29, 1\u201311 (2018).","journal-title":"Cell Cycle"},{"key":"1219_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bcp.2014.07.029","volume":"92","author":"J Michels","year":"2014","unstructured":"Michels, J. et al. MCL-1 dependency of cisplatin-resistant cancer cells. Biochem. Pharmacol. 92, 55\u201361 (2014).","journal-title":"Biochem. Pharmacol."},{"key":"1219_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2005.09.010","volume":"44","author":"W Sieghart","year":"2006","unstructured":"Sieghart, W. et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol. 44, 151\u2013157 (2006).","journal-title":"J. Hepatol."},{"key":"1219_CR41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ejmech.2018.01.076","volume":"146","author":"Y Wan","year":"2018","unstructured":"Wan, Y., Dai, N., Tang, Z. & Fang, H. Small-molecule Mcl-1 inhibitors: emerging anti-tumor agents. Eur. J. Med. Chem. 146, 471\u2013482 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"1219_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18368-w","volume":"7","author":"J Dey","year":"2017","unstructured":"Dey, J. et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition. Sci. Rep. 7, 18007 (2017).","journal-title":"Sci. Rep."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1219-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:29:06Z","timestamp":1671208146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1219-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["1219"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-1219-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"16 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of the said hospital. All the patients and healthy subjects were informed of the study purpose, and provided informed consent for participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"106"}}